Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Frequently asked questions
What sector does Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) operate in?
Lakewood-Amedex Biotherapeutics Inc. Common Stock belongs to the Other sector and operates in the Biotechnology industry.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) current stock price?
As of the latest data, Lakewood-Amedex Biotherapeutics Inc. Common Stock stock price is $0.29, with a previous close of $0.28. Lakewood-Amedex Biotherapeutics Inc. Common Stock gained $0.00 in the last trading session, representing a 1.06% increase.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) current market capitalization?
Lakewood-Amedex Biotherapeutics Inc. Common Stock market cap is approximately 677.73 thousand.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) Earnings Per Share (EPS)?
The trailing EPS is -$8.83, and the forward EPS is -$1.32.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) EBITDA?
Lakewood-Amedex Biotherapeutics Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.73 million.
Does Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) pay dividends?
No. Lakewood-Amedex Biotherapeutics Inc. Common Stock does not pay a dividend.
When is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) next earnings report?
Lakewood-Amedex Biotherapeutics Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) beta (volatility) score?
Lakewood-Amedex Biotherapeutics Inc. Common Stock has a beta of -0.887, indicating lower volatility than the overall market.
